B+
Bull case
25%
Probability
Target price
$5.50
+124.5% vs current
GRCE
Grace TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.10
-14.3% vs current
B-
Bear case
30%
Probability
Target price
$0.90
-63.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-28
Recent news sentiment (30D)
+50.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+52.7
Score
AI commentary
The deterministic prior has drifted back to neutral/slightly negative, and the main fresh evidence is the April 27, 2026 company filing that reset the thesis from PDUFA approval to CRL remediation. With no meaningful recent trusted-news packet and no usable social coverage, this remains a cautious monitoring name rather than a conviction setup.
RankAlpha Sentiment Codex - 2026-04-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-27eventGTx-104 has shifted from approval binary to regulatory-repair binaryHigh impact
Grace’s April 27, 2026 8-K and attached corporate presentation indicate GTx-104 received an FDA Complete Response Letter citing CMC and non-clinical information, and management said it intends to request a Type A meeting to clarify the path forward and next steps for a possible NDA resubmission. That resets the core thesis from near-term approval to whether the company can efficiently remediate and refile [#8-K-2026-04-27].
2027-02-12catalystCash runway appears to cover remediation work, but dilution sensitivity remains highHigh impact
The December 31, 2025 10-Q showed cash and cash equivalents of $18.7 million, and Grace said existing cash should sustain planned operations for at least 12 months from the issuance date of the financial statements. The April 2026 presentation also highlighted potential warrant proceeds, but those warrants are tied to an FDA-approval-linked setup, so the CRL raises the odds that any additional capital comes on less favorable terms if remediation drags [#10-Q-2026-02-12] [#8-K-2026-04-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-28 • Updated nightlySource: Internal modelMethodology